SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 06/10/21
UPCOMING DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 06/09/21
UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 06/08/21
Rosen, Global Investor Counsel, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action - ACADNewsfile Corp • 06/04/21
HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact its Attorneys Before June 18th Application Deadline in Securities Fraud LawsuitNewsfile Corp • 06/03/21
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 06/03/21
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related DisordersBusiness Wire • 06/03/21
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 06/02/21
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 06/01/21
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Acadia Pharmaceuticals Inc. Investors With Losses Over $100K to Secure Counsel Before Important June 18 Deadline in Securities Class Action - ACADPRNewsWire • 05/28/21
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) InvestorsPRNewsWire • 05/28/21
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 05/27/21
HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Securities Class Action Pending, June Deadline ApproachingNewsfile Corp • 05/24/21
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)PRNewsWire • 05/24/21
HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Securities Fraud Class Action FiledNewsfile Corp • 05/20/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm to Recover Losses Due to Alleged Securities FraudNewsfile Corp • 05/17/21
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)PRNewsWire • 05/13/21
ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys NowNewsfile Corp • 05/10/21
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
ACAD DEADLINE: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys NowNewsfile Corp • 05/05/21
